Organization · Venture Capital

BOLD Longevity Growth Fund

BOLD Longevity Growth Fund is a venture capital firm that invests in growth-stage companies focused on frontier biotechnologies addressing age-related diseases. The firm operates globally, emphasizing investments in longevity, biotechnology, and artificial intelligence.

Venture CapitalFunder

Official website Official pitch route

Overview

What BOLD Longevity Growth Fund does

What BOLD Longevity Growth Fund is

How it participates in the startup ecosystem

The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.

Operational profile

Organization status and context

Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.

Operational status: Active
Organization type: Venture Capital
Structured capabilities: Funder
Last reviewed: May 5, 2026

Official channels

Find BOLD Longevity Growth Fund elsewhere

Open the official website or a supported primary organization account.

WebsiteOfficial channel

Capability profile

BOLD Longevity Growth Fund as a funder

Official pitch route

Investment thesis

BOLD Longevity Growth Fund invests in growth-stage platform technologies that target biological aging as a root cause of disease, focusing on gene therapies, cell therapies, AI drug discovery, and AI-powered medical technologies.

Focus narrative

The firm targets growth-stage companies developing innovative platform technologies that enhance efficiency and safety in medical practices. BOLD Longevity Growth emphasizes co-investing with major biotech venture capital funds and pharmaceutical companies, particularly in sectors such as gene therapies, cell therapies, and AI-driven medical technologies.

Value beyond capital

BOLD Longevity Growth Fund adds value to its portfolio companies through strategic partnerships, leveraging its network of major biotech venture capital funds and pharmaceutical companies. The firm provides expertise in aging biology and access to resources that enhance the development and commercialization of innovative technologies aimed at improving healthspan.

Focus and fit

Stages: Growth Equity · Series B · Series B+
Sectors: Longevity & Anti-Aging Biotech & Life Sciences Artificial Intelligence Healthcare Regenerative Medicine
Regions: Global · United States

Availability

Currently deploying: Yes

Portfolio and track record

Recorded portfolio count: 8

Portfolio context

Notable portfolio companies include: BigHat Biosciences: A next-generation antibody company focused on advancing antibody-drug conjugates and other biologics for oncology and immunology. Verge Genomics: An AI-driven drug discovery company targeting neurodegenerative and autoimmune diseases, utilizing a proprietary brain tissue biobank. Proprio: A surgical navigation company that integrates AI-powered imaging and navigation technologies to enhance surgical precision. Aqtual: A precision diagnostics firm that uses cfDNA technology to provide insights for therapy selection in autoimmune and cancer treatments. Fountain Life: A precision health company that leverages advanced diagnostics for disease prevention and health optimization. Insilico Medicine: An AI drug discovery platform focused on longevity and biotechnology. Colossal: A de-extinction company developing technologies to revive extinct species. Oura: A company that develops biometric wearables for health tracking.

Connected ecosystem